Practice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelines.

BACKGROUNDS Despite a wide spectrum of contraceptive methods for women, the unintended pregnancy rate remains high (45% in the US), with 50% resulting in abortion. Currently, 20% of global contraceptive use is male-directed, with a wide variation among countries due to limited availability and lack of efficacy. Worldwide studies indicate that >50% of men would opt to use a reversible method, and 90% of women would rely on their partner to use a contraceptive. Additional reasons for novel male contraceptive methods to be available include the increased life expectancy, sharing the reproductive risks among partners, social issues, the lack of pharma industry involvement and the lack of opinion makers advocating for male contraception. AIM The present guidelines aim to review the status regarding male contraception, the current state of the art to support the clinical practice, recommend minimal requirements for new male contraceptive development and provide and grade updated, evidence-based recommendations from the European Society of Andrology (EAA) and the American Society of Andrology (ASA). METHODS An expert panel of academicians appointed by the EAA and the ASA generated a consensus guideline according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system. RESULTS Sixty evidence-based and graded recommendations were produced on couple-centered communication, behaviors, barrier methods, semen analysis and contraceptive efficacy, physical agents, surgical methods, actions before initiating male contraception, hormonal methods, non-hormonal methods, vaccines, and social and ethical considerations. CONCLUSION As gender roles transform and gender equity is established in relationships, the male contribution to family planning must be facilitated. Efficient and safe male-directed methods must be evaluated and introduced into clinical practice, preferably reversible, either hormonal or non-hormonal. From a future perspective, identifying new hormonal combinations, suitable testicular targets, and emerging vas occlusion methods will produce novel molecules and products for male contraception.

[1]  Michael G. Miller,et al.  Cardiovascular Safety of Testosterone-Replacement Therapy. , 2023, The New England journal of medicine.

[2]  R. Swerdloff,et al.  Design of an International Male Contraceptive Efficacy Trial Using a Self-Administered Daily Transdermal Gel Containing Testosterone and Segesterone Acetate (Nestorone®). , 2023, Contraception.

[3]  N. Parekh,et al.  Rising vasectomy volume following reversal of federal protections for abortion rights in the United States , 2023, International journal of impotence research.

[4]  C. Steegborn,et al.  On-demand male contraception via acute inhibition of soluble adenylyl cyclase , 2023, Nature Communications.

[5]  V. Hupertan,et al.  [Recommendations of the Committee of Andrology and Sexual Medicine of the AFU concerning the management of Vasectomy]. , 2023, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[6]  C. Lindsley,et al.  A selective inhibitor of the sperm-specific potassium channel SLO3 impairs human sperm function , 2023, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Nieschlag,et al.  Why we need more methods for male contraception , 2022, Andrology.

[8]  M. Labrecque,et al.  Men prefer pre-vasectomy consultation by telephone: a survey of vasectomized men. , 2022, The Canadian journal of urology.

[9]  R. Swerdloff,et al.  Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety. , 2022, The journal of sexual medicine.

[10]  S. Linsell,et al.  Less is More: Fulfillment of Opioid Prescriptions Before and After Implementation of a Modifier 22 Based Quality Incentive for Opioid-Free Vasectomies. , 2022, Urology.

[11]  S. Vij,et al.  The Omission of Genitourinary Physical Exam in Telehealth Pre-Vasectomy Consults Does Not Reduce Rates of Office Procedure Completion. , 2022, Urology.

[12]  M. Andreoletti,et al.  A defense of surgical procedures regulation , 2022, Theoretical Medicine and Bioethics.

[13]  A. Zini,et al.  UPDATE - 2022 Canadian Urological Association best practice report: Vasectomy. , 2022, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[14]  Annabelle M. Warren,et al.  Haematological actions of androgens. , 2022, Best practice & research. Clinical endocrinology & metabolism.

[15]  Wanhai Xu,et al.  An Ultrasound-Induced Self-Clearance Hydrogel for Male Reversible Contraception. , 2022, ACS nano.

[16]  Melissa Kottke,et al.  Patient-Centered Contraceptive Counseling , 2022, Obstetrics and gynecology.

[17]  A. Edelman,et al.  Contraception Selection, Effectiveness, and Adverse Effects: A Review. , 2021, JAMA.

[18]  M. Labrecque,et al.  Comparison of postal and non-postal post-vasectomy semen sample submission strategies on compliance and failures: an 11-year analysis of the audit database of the Association of Surgeons in Primary Care of the UK , 2021, BMJ Sexual & Reproductive Health.

[19]  W. White,et al.  Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men , 2021, Journal of cardiovascular pharmacology and therapeutics.

[20]  A. Salonia,et al.  European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. , 2021, European urology.

[21]  A. Wetzels,et al.  External quality control and training of semen analysis in the Netherlands: starting point for further reduction of outcome variability , 2021, Asian journal of andrology.

[22]  J. Amory,et al.  Emerging approaches to male contraception. , 2021, Fertility and sterility.

[23]  A. Karkhane,et al.  Evaluation of multi-epitope recombinant protein as a candidate for a contraceptive vaccine. , 2021, Journal of reproductive immunology.

[24]  M. Labrecque,et al.  Can a Low Sperm Concentration without Assessing Motility Confirm Vasectomy Success? A Retrospective Descriptive Study , 2021, The Journal of urology.

[25]  D. Young,et al.  Discovery and characterization of bromodomain 2–specific inhibitors of BRDT , 2021, Proceedings of the National Academy of Sciences.

[26]  Wei Yan,et al.  Triptonide is a reversible non-hormonal male contraceptive agent in mice and non-human primates , 2021, Nature Communications.

[27]  M. Meriggiola,et al.  Contraception across transgender , 2021, International Journal of Impotence Research.

[28]  J. Sandlow,et al.  Is Opioid-Free Post-Vasectomy Analgesia a Pain? A Single Surgeon Experience. , 2021, Urology.

[29]  E. Baldi,et al.  Distribution of semen examination results 2020 – A follow up of data collated for the WHO semen analysis manual 2010 , 2021, Andrology.

[30]  D. Blithe,et al.  Update on novel hormonal and non-hormonal male contraceptive development. , 2021, The Journal of clinical endocrinology and metabolism.

[31]  E. Goldberg The sperm-specific form of lactate dehydrogenase is required for fertility and is an attractive target for male contraception (a review) , 2020, Biology of Reproduction.

[32]  D. Ohl,et al.  Scheduling Appointments for Postvasectomy Semen Analysis Has No Impact on Compliance , 2020, European urology open science.

[33]  J. Trussler,et al.  Post-vasectomy semen analysis compliance with use of a home-based test. , 2020, The Canadian journal of urology.

[34]  M. Tomlinson,et al.  Is azoospermia the appropriate standard for post-vasectomy semen analysis? Or an unachievable goal of best practice laboratory guidelines , 2020, Human fertility.

[35]  B. Dahlbäck,et al.  Genetic risk factors for venous thromboembolism , 2020, Expert review of hematology.

[36]  D. Wolgemuth,et al.  Retinoic acid receptor antagonists for male contraception: current status† , 2020, Biology of Reproduction.

[37]  V. Triggiani,et al.  Critical evaluation of different available guidelines for late‐onset hypogonadism , 2020, Andrology.

[38]  J. Amory,et al.  "Shared Risk": Reframing Risk Analysis in the Ethics of Novel Male Contraceptives. , 2020, Contraception.

[39]  A. Salicioni,et al.  Testis-specific serine kinase protein family in male fertility and as targets for non-hormonal male contraception , 2020, Biology of Reproduction.

[40]  W. Evans,et al.  Systematic Review of Peer-Reviewed Literature on Global Condom Promotion Programs , 2020, International journal of environmental research and public health.

[41]  S. RamaRao,et al.  Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men , 2020, Drug Delivery and Translational Research.

[42]  J. Toppari,et al.  European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males , 2020, Andrology.

[43]  F. Grimstad,et al.  Contraception Across the Transmasculine Spectrum. , 2020, American journal of obstetrics and gynecology.

[44]  P. D. Andrews,et al.  A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity , 2020, eLife.

[45]  Christina Wang,et al.  Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins In Healthy Men. , 2020, The Journal of clinical endocrinology and metabolism.

[46]  M. Mohamed,et al.  Sexual Abstinence and Associated Factors Among Young and Middle-Aged Men: A Systematic Review. , 2020, The journal of sexual medicine.

[47]  G. Sawaya,et al.  Prevalence of Potentially Unnecessary Bimanual Pelvic Examinations and Papanicolaou Tests Among Adolescent Girls and Young Women Aged 15-20 Years in the United States. , 2020, JAMA internal medicine.

[48]  R. Walters,et al.  OPTIMIZING OPIOID PAIN MEDICATION USE AFTER VASECTOMY. A PROSPECTIVE STUDY. , 2019, Urology.

[49]  Eric Ballon-Landa,et al.  POOR COMPLIANCE WITH POST-VASECTOMY SEMEN TESTING: ANALYSIS OF FACTORS AND BARRIERS. , 2019, Urology.

[50]  J. Amory Development of Novel Male Contraceptives , 2019, Clinical and translational science.

[51]  T. Adam,et al.  Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. , 2019, JAMA internal medicine.

[52]  J. Jaffe,et al.  Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study. , 2019, The journal of sexual medicine.

[53]  G. Stackhouse,et al.  Routine Prescription of Opioids for Post-vasectomy Pain Control Associated with Persistent Use. , 2019, The Journal of urology.

[54]  S. Guha,et al.  Safety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): A clinical experience , 2019, The Indian journal of medical research.

[55]  J. Pharr,et al.  Behavioral Interventions to Increase Condom Use Among College Students in the United States: A Systematic Review , 2019, Health education & behavior : the official publication of the Society for Public Health Education.

[56]  R. Mieusset,et al.  Experimental mild increase in testicular temperature has drastic, but reversible, effect on sperm aneuploidy in men: A pilot study. , 2019, Reproductive biology.

[57]  R. Swerdloff,et al.  Combined nestorone–testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men , 2019, Andrology.

[58]  R. Swerdloff,et al.  Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel , 2018, Andrology.

[59]  R. Engelman,et al.  Family planning as a contributor to environmental sustainability: weighing the evidence , 2018, Current opinion in obstetrics & gynecology.

[60]  L. Chohan ACOG Committee Opinion No. 754: The Utility of and Indications for Routine Pelvic Examination. , 2018, Obstetrics and gynecology.

[61]  Christina Wang,et al.  Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill , 2018, The Journal of clinical endocrinology and metabolism.

[62]  E. Platz,et al.  Evaluation and Management of Testosterone Deficiency: AUA Guideline , 2018, The Journal of urology.

[63]  Frederick C W Wu,et al.  Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. , 2018, The Journal of clinical endocrinology and metabolism.

[64]  C. Copen Condom Use During Sexual Intercourse Among Women and Men Aged 15-44 in the United States: 2011-2015 National Survey of Family Growth. , 2017, National health statistics reports.

[65]  C. Premanandan,et al.  Reversibility of Vasalgel™ male contraceptive in a rabbit model , 2017, Basic and Clinical Andrology.

[66]  K. Piotrowska,et al.  Male hormonal contraception: hope and promise. , 2017, The lancet. Diabetes & endocrinology.

[67]  Susheela Singh,et al.  Contraceptive Failure in the United States: Estimates from the 2006–2010 National Survey of Family Growth , 2017, Perspectives on sexual and reproductive health.

[68]  K. Hardee,et al.  USE OF MALE METHODS OF CONTRACEPTION WORLDWIDE , 2016, Journal of Biosocial Science.

[69]  Frederick C W Wu,et al.  Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men. , 2016, The Journal of clinical endocrinology and metabolism.

[70]  N. K. Lohiya,et al.  Contraception with RISUG® and functional reversal through DMSO and NaHCO3 in male rabbits , 2016, Asian journal of andrology.

[71]  K. Curtis,et al.  U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[72]  L. Finer,et al.  Declines in Unintended Pregnancy in the United States, 2008-2011. , 2016, The New England journal of medicine.

[73]  R. Swerdloff,et al.  Male Hormonal Contraception: Where Are We Now? , 2016, Current Obstetrics and Gynecology Reports.

[74]  Christina Wang,et al.  Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. , 2014, Contraception.

[75]  C. Westhoff,et al.  The influence of oral contraceptive knowledge on oral contraceptive continuation among young women. , 2014, Journal of women's health.

[76]  W. Walker,et al.  The regulation of spermatogenesis by androgens. , 2014, Seminars in cell & developmental biology.

[77]  P. Treuting,et al.  Inhibition of Retinoic Acid Biosynthesis by the Bisdichloroacetyldiamine WIN 18,446 Markedly Suppresses Spermatogenesis and Alters Retinoid Metabolism in Mice* , 2014, The Journal of Biological Chemistry.

[78]  Yi-qun Gu,et al.  A randomized, controlled, multicenter contraceptive efficacy clinical trial of the intravas device, a nonocclusive surgical male sterilization , 2014, Asian journal of andrology.

[79]  E. Lynge,et al.  Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies , 2014, Journal of medical screening.

[80]  J. Trussell,et al.  The creeping Pearl: Why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? , 2013, Contraception.

[81]  C. Niederberger Re: Seminal and molecular evidence that sauna exposure affects human spermatogenesis. , 2013, The Journal of urology.

[82]  S. Martins,et al.  Use of Withdrawal and Unintended Pregnancy Among Females 15–24 Years of Age , 2013, Obstetrics and gynecology.

[83]  J. Stover,et al.  Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009 , 2013, Global Health: Science and Practice.

[84]  J. Duplisea,et al.  Compliance with semen analysis. , 2013, The Journal of urology.

[85]  Christina Wang,et al.  Functional role of progestin and the progesterone receptor in the suppression of spermatogenesis in rodents , 2013, Andrology.

[86]  M. Labrecque,et al.  Vasectomy: AUA guideline. , 2012, The Journal of urology.

[87]  Julio E. Agno,et al.  Small-Molecule Inhibition of BRDT for Male Contraception , 2012, Cell.

[88]  Christina Wang,et al.  A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. , 2012, The Journal of clinical endocrinology and metabolism.

[89]  A. Giwercman,et al.  European Association of Urology guidelines on vasectomy. , 2012, European urology.

[90]  E. Nieschlag,et al.  Hormonal male contraception in men with normal and subnormal semen parameters. , 2011, International journal of andrology.

[91]  R. Naz Antisperm Contraceptive Vaccines: Where We Are and Where We Are Going? , 2011, American journal of reproductive immunology.

[92]  G. Meduri,et al.  Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. , 2011, Human reproduction.

[93]  Yuriy Kirichok,et al.  The role of Hv1 and CatSper channels in sperm activation , 2010, The Journal of physiology.

[94]  A. Glasier Acceptability of contraception for men: a review. , 2010, Contraception.

[95]  J. Reel,et al.  The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[96]  W. Mosher,et al.  Use of contraception in the United States: 1982-2008. , 2010, Vital and health statistics. Series 23, Data from the National Survey of Family Growth.

[97]  L. Salkoff,et al.  The SLO3 sperm‐specific potassium channel plays a vital role in male fertility , 2010, FEBS letters.

[98]  Christina Wang,et al.  Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. , 2009, The Journal of clinical endocrinology and metabolism.

[99]  Judith Eberhardt,et al.  Attitudes towards the male contraceptive pill in men and women in casual and stable sexual relationships , 2009, Journal of Family Planning and Reproductive Health Care.

[100]  S. Song,et al.  Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. , 2009, The Journal of clinical endocrinology and metabolism.

[101]  K. Kahrizi,et al.  Human male infertility caused by mutations in the CATSPER1 channel protein. , 2009, American journal of human genetics.

[102]  H. Behre,et al.  Male hormonal contraception: a double-blind, placebo-controlled study. , 2008, The Journal of clinical endocrinology and metabolism.

[103]  W. Willis,et al.  Expression of the Gene for Mouse Lactate Dehydrogenase C (Ldhc) Is Required for Male Fertility1 , 2008, Biology of reproduction.

[104]  Frederick C W Wu,et al.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. , 2008, The Journal of clinical endocrinology and metabolism.

[105]  G. Guyatt,et al.  A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. , 2008, The Journal of clinical endocrinology and metabolism.

[106]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[107]  Yue Jia,et al.  transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis. , 2007, The Journal of clinical endocrinology and metabolism.

[108]  D. Clapham,et al.  KSper, a pH-sensitive K+ current that controls sperm membrane potential , 2007, Proceedings of the National Academy of Sciences.

[109]  J. Jones,et al.  A prospective evaluation of the impact of scheduled follow‐up appointments with compliance rates after vasectomy , 2007, BJU international.

[110]  C. Gnoth,et al.  The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple's sexual behaviour during the fertile time: a prospective longitudinal study. , 2007, Human reproduction.

[111]  S. Guha Biophysical mechanism-mediated time-dependent effect on sperm of human and monkey vas implanted polyelectrolyte contraceptive. , 2007, Asian journal of andrology.

[112]  W. Bremner,et al.  Miglustat has no apparent effect on spermatogenesis in normal men. , 2007, Human reproduction.

[113]  M. Mbizvo,et al.  10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. , 2006, Journal of andrology.

[114]  A. Matsumoto,et al.  Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. , 2006, The Journal of clinical endocrinology and metabolism.

[115]  Weili Lu,et al.  A phase II randomized controlled trial of a novel male contraception, an intra-vas device. , 2006, International journal of andrology.

[116]  M. Mbizvo,et al.  Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men. , 2006, Human reproduction.

[117]  H. Landy,et al.  Explaining ovulation awareness-based family planning methods , 2006 .

[118]  J. Reel,et al.  Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. , 2006, Endocrinology.

[119]  M. O'Rand,et al.  Eppin: An effective target for male contraception , 2006, Molecular and Cellular Endocrinology.

[120]  I. Shah,et al.  The acceptability of an injectable, once-a-month male contraceptive in China. , 2006, Contraception.

[121]  David Handelsman,et al.  Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis , 2006, The Lancet.

[122]  Zhaoyuan Hu,et al.  Transient testicular warming enhances the suppressive effect of testosterone on spermatogenesis in adult cynomolgus monkeys (Macaca fascicularis). , 2006, The Journal of clinical endocrinology and metabolism.

[123]  K. Schulz,et al.  Non-latex versus latex male condoms for contraception. , 2006, The Cochrane database of systematic reviews.

[124]  K. Herbst,et al.  Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. , 2005, Journal of andrology.

[125]  W. Bremner,et al.  Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. , 2005, The Journal of clinical endocrinology and metabolism.

[126]  F. Saad,et al.  Attitudes toward male fertility control: results of a multinational survey on four continents. , 2005, Human reproduction.

[127]  K. Petersen,et al.  Reversible Immunocontraception in Male Monkeys Immunized with Eppin , 2004, Science.

[128]  M. Nikula,et al.  Efficacy of the new TwoDay Method of family planning. , 2004, Fertility and sterility.

[129]  W. Bremner,et al.  Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men. , 2004, Journal of andrology.

[130]  J. Trussell Contraceptive failure in the United States. , 2004, Contraception.

[131]  Christina Wang,et al.  Male hormonal contraception. , 2004, American journal of obstetrics and gynecology.

[132]  A. Morselli-Labate,et al.  Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. , 2003, The Journal of clinical endocrinology and metabolism.

[133]  D. Clapham,et al.  CatSper1 required for evoked Ca2+ entry and control of flagellar function in sperm , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[134]  E. Nieschlag,et al.  A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. , 2003, The Journal of clinical endocrinology and metabolism.

[135]  David Handelsman,et al.  Contraceptive efficacy of a depot progestin and androgen combination in men. , 2003, The Journal of clinical endocrinology and metabolism.

[136]  M. Mbizvo,et al.  A review of androgen-progestin regimens for male contraception. , 2003, Journal of andrology.

[137]  Zhengjun Huang,et al.  A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. , 2003, The Journal of clinical endocrinology and metabolism.

[138]  R. Swerdloff,et al.  Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. , 2002, The Journal of clinical endocrinology and metabolism.

[139]  Irit Sinai,et al.  Efficacy of a new method of family planning: the Standard Days Method. , 2002, Contraception.

[140]  B. Silvestrini,et al.  Indazole carboxylic acids in male contraception. , 2002, Contraception.

[141]  E. Nieschlag,et al.  An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. , 2002, The Journal of clinical endocrinology and metabolism.

[142]  E. Nieschlag,et al.  Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. , 2001, Human reproduction.

[143]  A. Pollack,et al.  Efficacy of percutaneous vas occlusion compared with conventional vasectomy , 2000, BJU international.

[144]  R. Swerdloff,et al.  Testicular Heat Exposure Enhances the Suppression of Spermatogenesis by Testosterone in Rats: The "Two-Hit" Approach to Male Contraceptive Development. , 2000, Endocrinology.

[145]  P. Ho,et al.  Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. , 2000, Human reproduction.

[146]  R. Anakwe,et al.  Would women trust their partners to use a male pill , 2000 .

[147]  R. Swerdloff,et al.  Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. , 1998, The Journal of clinical endocrinology and metabolism.

[148]  J. Phillips,et al.  The meaning of abstinence for college students. , 1998 .

[149]  P. D. Griffin,et al.  Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. , 1998, International journal of andrology.

[150]  M. Brooks Men's views on male hormonal contraception-a survey of the views of attenders at a fitness centre in Bristol, UK. , 1998, The British journal of family planning.

[151]  L. Salkoff,et al.  Slo3, a Novel pH-sensitive K+ Channel from Mammalian Spermatocytes* , 1998, The Journal of Biological Chemistry.

[152]  W. Bremner,et al.  An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. , 1997, Fertility and sterility.

[153]  S. Guha,et al.  Phase II clinical trial of a vas deferens injectable contraceptive for the male. , 1997, Contraception.

[154]  Contraceptive efficacy of testosterone‐induced azoospermia and oligozoospermia in normal men , 1996, Fertility and sterility.

[155]  N. Adler,et al.  Adolescents and the Contraceptive Pill: The Impact of Beliefs on Intentions and Use , 1996, Obstetrics and gynecology.

[156]  G. Waites,et al.  Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. , 1996, Fertility and sterility.

[157]  D. Soebadi,et al.  Intravasal injection of formed-in-place medical grade silicone rubber for vas occlusion. , 1995, International journal of andrology.

[158]  R. Mieusset,et al.  The potential of mild testicular heating as a safe, effective and reversible contraceptive method for men. , 1994, International journal of andrology.

[159]  S. Guha,et al.  Phase I clinical trial of an injectable contraceptive for the male. , 1993, Contraception.

[160]  Zhang Shu-ping,et al.  Intravasal injection of formed‐in‐place silicone rubber as a method of vas occlusion , 1992 .

[161]  World Health Organisation Task Force ON Methods For The Fertility Contraceptive efficacy of testosterone-induced azoospermia in normal men , 1990, The Lancet.

[162]  M. Sexter,et al.  The high rate of noncompliance for post-vasectomy semen examination: medical and legal considerations. , 1990, The Journal of urology.

[163]  S C Zhao,et al.  Vas deferens occlusion by percutaneous injection of polyurethane elastomer plugs: clinical experience and reversibility. , 1990, Contraception.

[164]  L. Grummer-Strawn,et al.  Contraceptive failure of the ovulation method of periodic abstinence. , 1990, Family planning perspectives.

[165]  S. Qian,et al.  Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. , 1987, Contraception.

[166]  H. Grandjean,et al.  Inhibiting effect of artificial cryptorchidism on spermatogenesis. , 1985, Fertility and sterility.

[167]  W. President.,et al.  THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS , 1946 .

[168]  M. Baskin Temporary sterilization by the injection of human spermatozoa. A preliminary report , 1932 .

[169]  Bambang Prajoga Eko Wardoyo,et al.  Ethnomedicine Study on Justicia gendarussa for Male Contraception at the Nimboran Ethnic, Jayapura , 2022 .

[170]  Priya Keshari,et al.  Impact of Radiation on Male Fertility. , 2022, Advances in experimental medicine and biology.

[171]  OUP accepted manuscript , 2022, Human Reproduction.

[172]  K. Vogt,et al.  An Opioid Prescription for Men Undergoing Minor Urologic Surgery Is Associated with an Increased Risk of New Persistent Opioid Use. , 2019, European urology.

[173]  K. Hamil,et al.  Non-hormonal male contraception: A review and development of an Eppin based contraceptive. , 2016, Pharmacology & therapeutics.

[174]  R. Mclachlan,et al.  ReviewHormonal Regulation of Spermatogenesis in Primates and Man : Insights for Development of the Male Hormonal Contraceptive , 2002 .

[175]  E. Nieschlag,et al.  Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. , 2001, The Journal of clinical endocrinology and metabolism.

[176]  ACOG COMMITTEE OPINION , 2022 .